Group items tagged

Bristol-Myers Squibb Co. said Monday it is recalling eight production lots of its anti-clotting drug Coumadin because the amount of the active ingredient in the drug could change.

PBR Staff Writer Published 25 February 2014 Bristol-Myers Squibb (BMS) has received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) for its investigational DCV Dual Regimen (daclatasvir and asunaprevir) for use as a combination therapy in the treatment of genotype 1b chronic hepatitis C infection (HCV).